Tackling overweight and obesity in the youth with the PAS GRAS project

IF 58.7 1区 医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY
Afshan N. Malik, Anabela Marisa Azul, Eugénia Carvalho, John G. Jones, Paulo Matafome, Paulo J. Oliveira
{"title":"Tackling overweight and obesity in the youth with the PAS GRAS project","authors":"Afshan N. Malik, Anabela Marisa Azul, Eugénia Carvalho, John G. Jones, Paulo Matafome, Paulo J. Oliveira","doi":"10.1038/s41591-025-03721-8","DOIUrl":null,"url":null,"abstract":"<p>It is a startling reality that today, over 245 million children aged 5–14, 249 million adolescents and young adults aged 15–24, and 2.1 billion adults are overweight or obese, with substantial increases for all age groups predicted for 2050<sup>1,2</sup>. The younger cohorts in particular are consigned to a lifetime of obesity-related comorbidities, whose treatment will consume an increasingly larger fraction of healthcare resources, with estimated costs reaching US$4.32 trillion by 2035<sup>3</sup>.</p><p>Youth obesity is particularly concerning because of the unique vulnerabilities of this age group and requires early intervention and decades of management<sup>5</sup>. Indicators of early onset metabolic complications, such as redox and energy imbalances, DNA methylation and transcriptional alterations, are already present in pre-pubertal children with obesity, resulting in greater adulthood metabolic risks. Many, if not most, of the determinants of lifetime obesity and metabolic sequelae are established during early stages of life. Investment in early childhood, from preconception to adolescence, can yield a 10:1 benefit:cost ratio in health and socioeconomic outcomes during later life<sup>5</sup>.</p>","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"19 1","pages":""},"PeriodicalIF":58.7000,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41591-025-03721-8","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

It is a startling reality that today, over 245 million children aged 5–14, 249 million adolescents and young adults aged 15–24, and 2.1 billion adults are overweight or obese, with substantial increases for all age groups predicted for 20501,2. The younger cohorts in particular are consigned to a lifetime of obesity-related comorbidities, whose treatment will consume an increasingly larger fraction of healthcare resources, with estimated costs reaching US$4.32 trillion by 20353.

Youth obesity is particularly concerning because of the unique vulnerabilities of this age group and requires early intervention and decades of management5. Indicators of early onset metabolic complications, such as redox and energy imbalances, DNA methylation and transcriptional alterations, are already present in pre-pubertal children with obesity, resulting in greater adulthood metabolic risks. Many, if not most, of the determinants of lifetime obesity and metabolic sequelae are established during early stages of life. Investment in early childhood, from preconception to adolescence, can yield a 10:1 benefit:cost ratio in health and socioeconomic outcomes during later life5.

Abstract Image

通过PAS GRAS项目解决青少年超重和肥胖问题
令人震惊的现实是,今天,超过2.45亿5-14岁的儿童、2.49亿15-24岁的青少年和年轻人以及21亿成年人超重或肥胖,预计到2050年,所有年龄组的超重或肥胖人数都将大幅增加。尤其是年轻人群,他们一生中都有与肥胖相关的合并症,其治疗将消耗越来越多的医疗资源,估计到20353年成本将达到4.32万亿美元。青少年肥胖问题尤其令人担忧,因为这一年龄组具有独特的脆弱性,需要早期干预和数十年的管理。早发性代谢并发症的指标,如氧化还原和能量失衡、DNA甲基化和转录改变,已经存在于青春期前的肥胖儿童中,导致更大的成年代谢风险。许多(如果不是大多数的话)终生肥胖和代谢后遗症的决定因素是在生命的早期阶段确立的。对幼儿期(从孕前到青春期)的投资,在今后生活的健康和社会经济成果方面可产生10:1的效益:成本比。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Nature Medicine
Nature Medicine 医学-生化与分子生物学
CiteScore
100.90
自引率
0.70%
发文量
525
审稿时长
1 months
期刊介绍: Nature Medicine is a monthly journal publishing original peer-reviewed research in all areas of medicine. The publication focuses on originality, timeliness, interdisciplinary interest, and the impact on improving human health. In addition to research articles, Nature Medicine also publishes commissioned content such as News, Reviews, and Perspectives. This content aims to provide context for the latest advances in translational and clinical research, reaching a wide audience of M.D. and Ph.D. readers. All editorial decisions for the journal are made by a team of full-time professional editors. Nature Medicine consider all types of clinical research, including: -Case-reports and small case series -Clinical trials, whether phase 1, 2, 3 or 4 -Observational studies -Meta-analyses -Biomarker studies -Public and global health studies Nature Medicine is also committed to facilitating communication between translational and clinical researchers. As such, we consider “hybrid” studies with preclinical and translational findings reported alongside data from clinical studies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信